Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of patients with multidrug-resistant tuberculosis
Christoph Lange, Rob E. Aarnoutse, J. W. C. Alffenaar, et al.
The International Journal of Tuberculosis and Lung Disease (2019) Vol. 23, Iss. 6, pp. 645-662
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
Giovanni Battista Migliori, Simon Tiberi, Alimuddin Zumla, et al.
International Journal of Infectious Diseases (2020) Vol. 92, pp. S15-S25
Open Access | Times Cited: 191
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement
José Domínguez, Martin J. Boeree, Emmanuelle Cambau, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 4, pp. e122-e137
Closed Access | Times Cited: 57
Multidrug-resistant tuberculosis
Keertan Dheda, Fuad Mirzayev, Daniela María Cirillo, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 55
Microfluidic systems for infectious disease diagnostics
Thomas Lehnert, Martin A. M. Gijs
Lab on a Chip (2024) Vol. 24, Iss. 5, pp. 1441-1493
Open Access | Times Cited: 16
Clinical standards for the dosing and management of TB drugs
Jan‐Willem C. Alffenaar, Sophie L. Stocker, Lina Davies Forsman, et al.
The International Journal of Tuberculosis and Lung Disease (2022) Vol. 26, Iss. 6, pp. 483-499
Open Access | Times Cited: 49
MDR Tuberculosis Treatment
Juan Espinosa‐Pereiro, Adrián Sánchez‐Montalvá, María Luisa Aznar, et al.
Medicina (2022) Vol. 58, Iss. 2, pp. 188-188
Open Access | Times Cited: 39
Current and future treatments for tuberculosis
Anthony Lee, Yingda L. Xie, Clifton E. Barry, et al.
BMJ (2020), pp. m216-m216
Closed Access | Times Cited: 59
Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencing
Doctor B. Sibandze, Alexander Kay, Viola Dreyer, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 37
Availability and costs of medicines for the treatment of tuberculosis in Europe
Gunar Günther, Lorenzo Guglielmetti, Claude Leu, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 1, pp. 77-84
Open Access | Times Cited: 32
Clinical Outcomes among Patients with Drug-resistant Tuberculosis receiving Bedaquiline or Delamanid Containing Regimens
R. R. Kempker, Lali Mikiashvili, Ying Zhao, et al.
Clinical Infectious Diseases (2019) Vol. 71, Iss. 9, pp. 2336-2344
Open Access | Times Cited: 47
Tuberkulose im Erwachsenenalter
Tom Schaberg, Folke Brinkmann, Cornelia Feiterna‐Sperling, et al.
Pneumologie (2022) Vol. 76, Iss. 11, pp. 727-819
Open Access | Times Cited: 24
Epidemiological study of Mycobacterium Tuberculosis in Baghdad Governorate, Iraq
Ahmed Abduljabbar Jaloob Aljanaby, Qassim Muhsin Hashim Al-Faham, Israa Abduljabbar Jaloob Aljanaby, et al.
Gene Reports (2021) Vol. 26, pp. 101467-101467
Closed Access | Times Cited: 27
Telemedicine as a tool to prevent multi-drug resistant tuberculosis in poor resource settings: Lessons from Nigeria
Kikelomo Sabainah Olowoyo, Deborah Tolulope Esan, Benedict Tolulope Adeyanju, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases (2024) Vol. 35, pp. 100423-100423
Open Access | Times Cited: 4
An Exploratory Review of the Potential of Lytic Proteins and Bacteriophages for the Treatment of Tuberculosis
Sibongile Mtimka, Priyen Pillay, Lusisizwe Kwezi, et al.
Microorganisms (2024) Vol. 12, Iss. 3, pp. 570-570
Open Access | Times Cited: 4
Treatment completion of drug-resistant tuberculosis in Ethiopia: A perspective from healthcare users
Ahmed Reshid Tusho, Sheila Mokoboto-Zwane
PLOS Global Public Health (2025) Vol. 5, Iss. 2, pp. e0004110-e0004110
Open Access
Identification of novel natural inhibitors of Mycobacterium tuberculosis DNA-directed RNA polymerase via extensive computational screening and MMGBSA
Muhammad Bilal Azmi, Muhammad Waqas, Shahid Durran, et al.
Journal of Molecular Liquids (2025), pp. 127360-127360
Closed Access
A Transcriptomic Biomarker Predicting Linezolid-Associated Neuropathy During Treatment of Drug-Resistant Tuberculosis
Nika Zielinski, Dragoș Băiceanu, Antonela Dragomir, et al.
Pathogens and Immunity (2024) Vol. 9, Iss. 2, pp. 25-42
Open Access | Times Cited: 3
Between Curing and Torturing: Burden of Adverse Reaction in Drug-Resistant Tuberculosis Therapy
Yudisia Ausi, Prayudi Santoso, Deni Kurniadi Sunjaya, et al.
Patient Preference and Adherence (2021) Vol. Volume 15, pp. 2597-2607
Open Access | Times Cited: 23
Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma
Xubin Zheng, Erwin M. Jongedijk, Yi Hu, et al.
Journal of Chromatography B (2020) Vol. 1158, pp. 122397-122397
Open Access | Times Cited: 22
Design, Synthesis, Evaluation of Antitubercular Activity and Insilco Studies of Novel 1,5‐Naphthyridin‐2(1H)‐one Pendent 1,2,3‐Triazoles
Nagendra Babu Chilakala, Arnab Roy, Nitin Pal Kalia, et al.
Chemistry & Biodiversity (2024) Vol. 21, Iss. 12
Closed Access | Times Cited: 2
Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report
Johanna Erber, Simon Weidlich, Tristan Tschaikowsky, et al.
BMC Infectious Diseases (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 19
<p>Barriers and Strategies: A Review of Access to Affordable Multi-Drug Resistant Tuberculosis Medication in China</p>
Yuou Zhang, Xuan Liu, Linghe Yang, et al.
Infection and Drug Resistance (2020) Vol. Volume 13, pp. 3679-3687
Open Access | Times Cited: 15
Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid
Hoon Hee Lee, Kyung‐Wook Jo, Jae‐Joon Yim, et al.
International Journal of Infectious Diseases (2020) Vol. 98, pp. 478-485
Open Access | Times Cited: 14
Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: A retrospective cohort study
Innocent Murhula Kashongwe, Fina Mawete, Leopoldine Mbulula, et al.
PLoS ONE (2020) Vol. 15, Iss. 8, pp. e0236264-e0236264
Open Access | Times Cited: 14
A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis
Thomas Mercier, Vincent Desfontaine, S. Cruchon, et al.
Journal of Chromatography B (2022) Vol. 1211, pp. 123456-123456
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top